Meprospan advertisement, 1967. |
JAMA: The Journal of the American Medical Association, Vol. 199, No. 2, pp. 226-228.
Her kind of pressures last all day... shouldn't her tranquilizer?
Meprospan® /400 (meprobamate) 400 mg.   ~   sustained-release tranquilizer for sustained anxiety and tension
Daytime dose helps keep patient calm throughout the day   ~   Nighttime dose fosters restful sleep throughout the night
Please turn page for brief summary of prescribing information
Precautions: Careful supervision of dose and amounts prescribed is advised. Consider possibility of dependence, particularly in patients with history of drug or alcohol addiction; it should be noted, however, that dependence on 'Meprospan' has not been reported to date. Withdraw gradually after use for weeks or months at excessive dosage. Abrupt withdrawal may precipitate recurrence of pre-existing symptoms, or withdrawal reactions including, rarely, epileptiform seizures. Should meprobamate cause drowsiness or visual disturbances, the dose should be reduced and operation of motor vehicles or machinery or other activity requiring alertness should be avoided if these symptoms are present. Effects of excessive alcohol may possibly be increased by meprobamate. Grand mal seizures may be precipitated in persons suffering from both grand and petit mal. Prescribe cautiously and in small quantities to patients with suicidal tendencies.
Side effects: Infrequent side effects of 'Meprospan' have included drowsiness and dizziness. Rare side effects have included urticaria, headache, nausea, erythema multiforme, vertigo and euphoria. The following side effects may be associated with administration of meprobamate in conventional tablet form.
Meprobamate -- Drowsiness may occur and, rarely, ataxia, usually controlled by decreasing the dose. Allergic or idiosyncratic reactions are rare, generally developing after one to four doses. mild reactions are characterized by an urticarial or erythematous, maculopapular rash. Acute nonthrombocytopenic purpura with peripheral edema and fever, transient leukopenia, and a single case of fatal bullous dermatitis after administration of meprobamate and prednisolone have been reported. More severe and very rare cases of hypersensitivity may produce fever, chills, fainting spells, angioneurotic edema, bronchial spasms, hypotensive crises (1 fatal case), anuria, anaphylaxis, stomatitis and proctitis. Treatment should be symptomatic in such cases, and the drug should not be reinstituted. Isolated cases of agranulocytosis, thrombocytopenic purpura, and a single fatal instance of aplastic anemia have been reported, but only when other drugs known to elicit these conditions were given concomitantly. Fast EEG activity has been reported, usually after excessive meprobamate dosage. Suicidal attempts may produce lethargy, stupor, ataxia, coma, shock, vasomotor and respiratory collapse.
Before prescribing, consult package circular.   Wallace Pharmaceuticals / Cranbury, N.J.